Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gore

Showing results (111-120 of 138) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 13, 2020
Ano-uro-genital mucosal melanoma UK national guidelinesHenry G Smith, Izhar Bagwan, Ruth E Board, et al.
The Lancet. Oncology|July 12, 2017
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysisSamra Turajlic, Kevin Litchfield, Hang Xu, et al.
International Journal of Cancer|May 18, 2010
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialMarkus M Heiss, Pawel Murawa, Piotr Koralewski, et al.
Gynecologic Oncology|April 22, 2019
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumorMartin Gore, Allan Hackshaw, William E Brady, et al.
Genome Medicine|August 13, 2010
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsCharles Swanton, James M Larkin, Marco Gerlinger, et al.
The Lancet. Oncology|April 22, 2014
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 studyPippa G Corrie, Andrea Marshall, Janet A Dunn, et al.
The Journal of Pathology|November 19, 2016
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis modelsVictoria L Bridgeman, Peter B Vermeulen, Shane Foo, et al.
Nature Genetics|February 4, 2014
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencingMarco Gerlinger, Stuart Horswell, James Larkin, et al.
The New England Journal of Medicine|March 9, 2012
Intratumor heterogeneity and branched evolution revealed by multiregion sequencingMarco Gerlinger, Andrew J Rowan, Stuart Horswell, et al.
Immunity|April 16, 2017
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established TumorsFrederick Arce Vargas, Andrew J S Furness, Isabelle Solomon, et al.
Pageof 14

Showing results (111-120 of 138) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|June 13, 2020
Ano-uro-genital mucosal melanoma UK national guidelinesHenry G Smith, Izhar Bagwan, Ruth E Board, et al.
The Lancet. Oncology|July 12, 2017
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysisSamra Turajlic, Kevin Litchfield, Hang Xu, et al.
International Journal of Cancer|May 18, 2010
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialMarkus M Heiss, Pawel Murawa, Piotr Koralewski, et al.
Gynecologic Oncology|April 22, 2019
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumorMartin Gore, Allan Hackshaw, William E Brady, et al.
Genome Medicine|August 13, 2010
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsCharles Swanton, James M Larkin, Marco Gerlinger, et al.
The Lancet. Oncology|April 22, 2014
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 studyPippa G Corrie, Andrea Marshall, Janet A Dunn, et al.
The Journal of Pathology|November 19, 2016
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis modelsVictoria L Bridgeman, Peter B Vermeulen, Shane Foo, et al.
Nature Genetics|February 4, 2014
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencingMarco Gerlinger, Stuart Horswell, James Larkin, et al.
The New England Journal of Medicine|March 9, 2012
Intratumor heterogeneity and branched evolution revealed by multiregion sequencingMarco Gerlinger, Andrew J Rowan, Stuart Horswell, et al.
Immunity|April 16, 2017
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established TumorsFrederick Arce Vargas, Andrew J S Furness, Isabelle Solomon, et al.
Pageof 14